Immunocore Holdings PLC

NASDAQ:IMCRUnited States

Today

Show headlines and story abstract

• DJ Immunocore Holdings Price Target Maintained With a $81.00/Share by Needham, from 4 hours ago by Dow Jones

  4 hours ago by Dow Jones
  Companies Mentioned: IMCR
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/IMCR/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 29, 2024 12:26 ET (16:26 GMT)
  

• Immunocore Converts Skin Cancer Therapy Phase 2/3 Trial to Phase 3, from 8 hours ago by MT Newswires

  8 hours ago by MT Newswires
  Companies Mentioned: IMCR
  08:14 AM EDT, 05/29/2024 (MT Newswires) -- Immunocore Holdings (IMCR) said Wednesday a phase 2/3 trial evaluating its therapy candidate, Kimmtrak as a monotherapy and in combination with pembrolizumab to treat certain patients with skin cancer has b...

• Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma, from 9 hours ago by GlobeNewswire

  9 hours ago by GlobeNewswire
  Companies Mentioned: IMCR

• Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma, from 9 hours ago by Dow Jones

  9 hours ago by Dow Jones
  Companies Mentioned: IMCR
  
  This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "plan," "anticipate," "estimate," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the expected clinical benefits of KIMMTRAK; the potential of KIMMTRAK for patients with uveal and cutaneous melanoma; and the Company's expectations regarding the design, progress, timing, randomization and scope of the Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma. Any forward-looking statements are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company's control. These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions on the Company's business, financial position, strategy and anticipated milestones, including Immunocore's ability to conduct ongoing and planned clinical trials; Immunocore's ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any future approved products, including as a result of health epidemics or pandemics, war in Ukraine, the conflict between Hamas and Israel, the broader risk of a regional conflict in the Middle East, or global geopolitical tension; Immunocore's ability to obtain and maintain regulatory approval of its product candidates, including KIMMTRAK; Immunocore's ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market and sell KIMMTRAK and any future approved products; Immunocore's ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; Immunocore's ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; Immunocore's need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including inflation, interest rates and unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict between Hamas and Israel, and global geopolitical tension; Immunocore's ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any of its product candidates it or its collaborators are developing; and the success of Immunocore's current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section titled "Risk Factors" in Immunocore's filings with the Securities and Exchange Commission, including Immunocore's most recent Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission on February 28, 2024, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information, except as required by law.